Analysts Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Price Target at $30.00

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) have earned a consensus recommendation of “Buy” from the six analysts that are covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $30.00.

Separately, HC Wainwright upgraded shares of Avalo Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research report on Monday, June 2nd.

Avalo Therapeutics Trading Up 1.8%

Shares of AVTX stock opened at $6.66 on Monday. The company has a fifty day moving average price of $4.95 and a two-hundred day moving average price of $5.92. Avalo Therapeutics has a one year low of $3.39 and a one year high of $16.00.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings results on Monday, May 12th. The company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.18). On average, research analysts expect that Avalo Therapeutics will post -19.07 EPS for the current year.

Hedge Funds Weigh In On Avalo Therapeutics

Hedge funds have recently bought and sold shares of the company. Nantahala Capital Management LLC purchased a new position in shares of Avalo Therapeutics in the 1st quarter worth about $7,209,000. Affinity Asset Advisors LLC boosted its stake in Avalo Therapeutics by 1,123.9% in the fourth quarter. Affinity Asset Advisors LLC now owns 550,765 shares of the company’s stock worth $4,092,000 after buying an additional 505,765 shares in the last quarter. RWA Wealth Partners LLC purchased a new stake in Avalo Therapeutics in the first quarter worth approximately $2,505,000. Velan Capital Investment Management LP purchased a new stake in shares of Avalo Therapeutics during the fourth quarter valued at approximately $817,000. Finally, Geode Capital Management LLC lifted its stake in Avalo Therapeutics by 937.0% in the fourth quarter. Geode Capital Management LLC now owns 104,853 shares of the company’s stock worth $779,000 after acquiring an additional 94,742 shares during the period. 87.06% of the stock is owned by hedge funds and other institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.